Lamictal XR Approved

Those with stakes in GlaxoSmithKline (NYSE: GSK) were pleased this morning as the stock rose on account of the FDA’s approval of Lamictal XR (“extended release”) . The drug, aimed at epilepsy patients thirteen years of age and older, is intended to reduce seizures in patients who have had unsuccessful results with other therapies.

You might also like

Leave A Reply

Your email address will not be published.

1 Comment
  1. Oscar says

    Not to mention that GlaxoSmithKline markets Relenza (Zanamivir), effective against A H1N1 (previously known as swine flu) and which is almost as good as Roche’s Tamiflu. 😉